Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Dose-response study of gevokizumab (S 78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, parallel-group, placebo controlled study

Project: Types of projectsProject

View graph of relations

ID: 44814800